INNOVENT BIO (01801.HK) Stock Community - Hot Topic Discussions

Quote List Quote List

Event Tracking

Dec19

JPMorgan Sees Opportunities in China's Healthcare Sector, Recommends Biotech and CXO Stocks

02:54

Dec15

Innovent Biologics' Masdutide Receives Approval from Macau's Drug Regulatory Authority

07:10

Dec12

Innovent Biologics Announces Success of Mazdutide Phase 1b Clinical Trial and Plans to Initiate Phase 3 Trial

00:00

Dec10

Innovent Biologics Initiates First-in-Human Trial of IBI3011 and Reports Positive Phase 2 Results for IBI128

00:27

Dec9

JPMorgan Publishes Report Analyzing Reasons for Sinovac Biotech's Stock Price Drop and Future Prospects

08:02

Innovent Biologics' PECONDLE® Successfully Completes Phase III Trial for Moderate to Severe Plaque Psoriasis and Receives Approval from NMPA

00:00

Schedules & Filings

Schedules

Filings

Aug27

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 3.258 B, Net Income 456.59 M, EPS 0.2681

Mar26

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 2.909 B, Net Income 158.51 M, EPS 0.0951

Aug28

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 2.123 B, Net Income -210.94 M, EPS -0.1299

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change